Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 2026

Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024.

Accesswire • Feb 5, 2026

Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets

PALO ALTO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has made a $20 million strategic investment in Quantum Scan Holdings, Inc. (“Quantum Scan”), a breakthrough medical technology company, targeting trillion-dollar market of preventive diagnosis and prognosis of human diseases and illness.

GlobeNewsWire • Jan 30, 2026

Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced that it has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the Company's litigation and intellectual property counsel.

GlobeNewsWire • Jan 2, 2026

Scilex Holding Company Confirms Dream Bowl 2026 Meme Coin Claim Process on December 24, 2025 Drop by Datavault AI Inc.

PALO ALTO, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced confirmed Dream Bowl 2026 Meme Coins claim process on December 24, 2025.

GlobeNewsWire • Dec 23, 2025

Scilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc., Completing Its Two-Tranche Equity Financing in Datavault AI Inc.

PALO ALTO, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that it has closed the second tranche of its strategic investment in Datavault AI in BTC (based on the spot exchange rate of BTC as of the signing of the strategic investment). The closing of this second tranche followed the approval by the Datavault stockholders at Datavault's November 24, 2025 annual meeting of the issuance of the shares of Datavault common stock upon exercise of the pre-funded warrant. Scilex's shares of Datavault common stock issued upon the exercise in full of the pre-funded warrant have an approximate value of $583.3 million based on the closing price of $2.21 per share of Datavault AI common stock on the Nasdaq Capital Market on November 25, 2025.

GlobeNewsWire • Nov 26, 2025

Scilex Holding Company Announces Closing of Exercise of Warrants for $20.3 Million Gross Proceeds

PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of (i) 428,572 shares of common stock (the “Common Stock”) having an exercise of $38.50 per share and issued in April 2024 (the “April 2024 Warrants”) and (ii) 475,824 shares of Common Stock having an exercise price of $22.72 per share and issued in December 2024 (together with the April 2024 Warrants, the “Existing Warrants”) at a reduced exercise price of $22.51 per share. The aggregate gross proceeds from the exercise of the Existing Warrants were approximately $20.3 million, before deducting placement agent fees and other offering expenses payable by the Company.

GlobeNewsWire • Nov 25, 2025

Scilex Holding Company Announces Exercise of Warrants for $20.3 Million Gross Proceeds

PALO ALTO, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of (i) 428,572 shares of common stock (the “Common Stock”) having an exercise of $38.50 per share and issued in April 2024 (the “April 2024 Warrants”) and (ii) 475,824 shares of Common Stock having an exercise price of $22.72 per share and issued in December 2024 (together with the April 2024 Warrants, the “Existing Warrants”).

GlobeNewsWire • Nov 24, 2025

Scilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc.

PALO ALTO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that, with respect to the voluntary distribution by Datavault AI Inc. (“Datavault AI”) (Nasdaq: DVLT) of Dream Bowl 2026 Meme Coins to record holders of Scilex common stock, given that such distribution is being made by Datavault AI as a token of its appreciation for Scilex's relationship with Datavault AI as a stockholder of Datavault AI, licensing partner and co-sponsor of the Dream Bowl XIV event to be held on January 11, 2026, Nasdaq has informed Datavault AI that it is not planning to make any announcement for Scilex regarding such distribution, whether as to the record date or an ex-dividend date. Notwithstanding the absence of such announcement, Datavault AI has informed the Company that it intends to make such voluntary distribution to record holders of Scilex common stock as of November 25, 2025 concurrently with the distribution of the Dream Bowl 2026 Meme Coins to Datavault AI's eligible record equity holders, including the Company.

GlobeNewsWire • Nov 21, 2025

Scilex Holding Company Announces that the Board of Directors of Datavault AI Inc. Has Approved the Distribution of a Dream Bowl 2026 Meme Coin to All Eligible Scilex and Datavault AI Stockholders of Record and Set a Record Date of November 25, 2025

PALO ALTO, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the Board of Directors of Datavault AI Inc. (“Datavault AI”) (Nasdaq: DVLT) has approved the distribution of a Dream Bowl 2026 Meme Coin to all [eligible] Scilex and Datavault AI stockholders of record and set a record date of November 25, 2025 for determining stockholders entitled to receive the Dream Bowl 2026 Meme Coin from Datavault AI.

GlobeNewsWire • Nov 11, 2025

Scilex Holding Company Announces Worldwide Exclusive License for Tokenization and Monetization of Real-World Asset (RWA) in Genomic, DNA Data, Diagnosis, Therapeutics Products, Genetic and Drug information from Datavault AI

PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has in-licensed a worldwide exclusive license, with right to sublicense, to Datavault AI's proprietary AI-driven technology for the use within the biotech and biopharma industry, specifically enabling the creation and operation of a Biotech Exchange platform. This license allows Scilex to leverage Datavault AI's advanced data platforms for secure tokenization, trading, and monetization of biotech assets, including genomic, DNA data, diagnostic, therapeutic products, genetic and drug information, marking a significant step forward in the commercialization of biotech innovations.

GlobeNewsWire • Nov 4, 2025